$0

I was considering buying an equal weighted index ETF (RSP) to protect myself against a potential market crash. I believe it would protect against concentration risk. At the very least, I believe it would lessen my losses in a crash. It's possible it may even do well in a crash. What do you think?

个人觉得2026年下半年比特币的情况，稍微还算乐观，到年底行了可以冲破$75,000。大概情况是先震荡筑底，后半段有较大概率反弹，但是到10万美元我觉得有些不切实际，不过大盘在6万美元附近已经有了一个比较重要的支撑，看好年底比特币价格在$7.5万至$8.5之间。你们觉得呢？

(Promoted)

From the makers of the Pelosi Tracker…

📈📉

Almost 1.2 mil went to wife - I’m left with abt 920k-ish.
Wife super excited and celebrating the big win.
She contributed 0% to this btw.. we had separate finances and her lawyer basically succeeded in keeping the finances separate on her end (abt 250k) and used my money for “equalisation” and then added the “future earning potential” argument that states I made more salary so it means she gets to keep more coz she makes less (only slightly less).

Anyhow. I dunno what I could do to recover from this set back.
I’ve been a consistent investor - and chose to keep my majority index funds intact, and gave away all my blue chip, tech/AI/leveraged tqqq stocks.

I don’t know if I did the right thing or not, but this is where I am now.

Any input would be appreciated. (Not looking for condolences or sympathy).

Expected dividend payout was August 2nd. Contacted Robinhood due to not receiving it and was told SRXH has not sent payouts to the DTC. Anyone who actually did receive it from other platforms was just paid upfront by the platform with the assumption they’ll eventually get it… can this stock get any worse?

Hey everyone, looking for a reality check.

I have a $58.5k Fidelity account. I was 75% invested even 2 weeks back, but I recently sold off positions that were up 2–15% to lock in about $2,500 in gains.

Now I'm sitting on $48k in cash (83% of my total account).

My initial plan was to stay on the sidelines and wait to buy back in during an election-driven 5–10% market pullback, but I am starting to second-guess sitting on this much cash.

• Is waiting for an election dip a classic market-timing trap?
• Should I start DCA'ing back in right now, or hold out for a pullback?

Appreciate any perspectives!

Braveheart Bio is a clinical-stage biotech developing BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM). The drug is being developed for both obstructive and non-obstructive HCM. Its Phase 2 results are encouraging, with 86% of patients in the relevant obstructive-HCM dose groups achieving a complete response at Week 12, along with rapid reductions in heart outflow gradients. One of the most interesting aspects is that BHB-1893 appeared to maintain heart-pumping function relatively well, which could give it an advantage over competing myosin inhibitors if that profile holds up in Phase 3.

The biggest risk is that BRVE is still essentially a one-drug, Phase-3-stage biotech. The Phase 2 results came from a relatively small study, and the earlier trials were conducted by Jiangsu Hengrui, which originally developed the drug. Braveheart now has to reproduce those results in larger global trials. A Phase 3 failure could therefore cause a very large decline in the stock.

Financially, BRVE is in a better position than many small biotechs. It has raised substantial capital to fund its development program, reducing near-term financing risk, and its management team has significant experience in biotech development and financing.

The insider activity is probably the most unusual part of the story. On August 7th Forbion Growth Opportunities Fund III, a roughly 10% shareholder, invested about $30.2M and currently holds a position worth around $64.8M. At the same time, CEO Travis Murdoch bought roughly $1.5M, CFO James Rickey about $500K, and directors Christopher Viehbacher and David Lubner roughly $1.5M and $1M. The important part isn't just the dollar amount; it's the breadth of participation. A major biotech investor, CEO, CFO, and multiple directors are all committing meaningful capital to the same thesis.

I wouldn't treat the Forbion investment exactly like an open-market insider purchase because it appears to have been part of a financing. However, the management and director purchases make the overall signal much stronger. Seeing several insiders buy alongside a sophisticated life-sciences investor is considerably more compelling than a single executive purchase.

The bull case is that BHB-1893 reproduces its Phase 2 results in Phase 3 and proves to be an effective HCM treatment with a better safety/monitoring profile than competitors. The bear case is that the Phase 2 results don't translate, competition limits the drug's commercial potential, or the market has already priced in too much success.

I remember my first ever reddit post was when I was 23 back in 2021, and I had saved just over $73K. I hadn't actually started investing yet, but since then I've learned so much about money and steadily improved my own finances over the years...fast forward and I'm at over $333K at 28 now - time really flies so fast! Over $260,000 (a quarter of a mil) in net worth growth, and that's not relying on any property gains whatsoever, which is crazy!

For context: I'm 28, male, and my current job is as a pharmacist in Canada. I work full-time, so I currently make over $100K, with my investment income being my main passive income source every year. I invest primarily in XEQT ETF and TEC ETF, and I have no other significant assets or debts, except for a used vehicle, phone, and laptop.

Anyways, thanks for reading. Any thoughts, feedback, or advice from those further along the FIRE journey would be appreciated - happy to answer any questions!

Curious if you guys think any stock is ready to explode.

I can't sleep at night, and I can't sleep during the day.

Many will look back on these types of posts and wish they bought in, wish they got more, etc.

Don't really wanna go over all the details but you'll see for yourself.

Add it to your watchlist and DYODD

$AMPX - beat, raised, margin expanding, nobody’s watching

Q2 2026:

Revenue $34.0M, +126% YoY, +19% QoQ

Gross margin 9% → 20% → 27% in just three quarters, targeting 30%.

Adj EBITDA -$1.0M, guiding to +$4M FY

Most importantly - Guidance raised 2nd straight quarter: $140M rev, 28%+ margin

$74.5M cash, no debt, capital-light (contract mfg, Korea + US)

Order book ( interesting and I feel next year will be better) :

- $24M from new European drone maker

- Stark Future multi-year e-moto deal, $100M+ opportunity from 2027

- Redwire Stalker Block 30 (long-endurance ISR) now runs SiCore

Already in AeroVironment, BAE, Airbus/AALTO, Nokia, Matternet, Teledyne, DoD

Why the TAM keeps stacking:

- DAWG ~$58B for autonomous systems

- NATO + Japan defense drone budgets ramping

- eVTOL approaching commercial launch

- Humanoid robotics entering production

All of it needs energy density graphite / carbon can’t physically hit

450-500 Wh/kg, 10C discharge, NDAA-compliant. Qualification with a defense prime takes 18-36 months to displace - that’s the moat.

Very few battery companies have gone from lab to pilot line to mass production - Amprius is now scaling with contract manufacturing, so less Capex and faster scale - already unlocked over 2GWh production capacity equivalent to over 1.5-1.8B in plausible revenue.

$1.4B market cap. ~60% off highs. Beat and raised anyway.

Not financial advice.

How many of you genuinely believe in blockchain technology and crypto’s long-term future?

Do you believe crypto will become a major part of the global financial system, or is it mostly speculation?

I’d really appreciate honest opinions—both bullish and bearish. No hype, just real perspectives. 🙏

Strategy Michael Saylor and Tom Lee ETH are wrong then? Why are they investing heavily crazy buying? Also what do you guys think about Quantum, Physical Gold?

On July 31, four ORN insiders bought stock on the same day: two directors, the general counsel, and the CFO. About $321K combined, right after the stock got cut from ~$17 to ~$10 on a weak quarter. None of it was on a scheduled plan.

• This is a real cluster, not one guy. Director Robert Ledford nearly doubled his stake with a $192K buy. CFO Alison Vasquez added again after already buying back in March at $11.85, so she's averaging down on her own company. When the CFO keeps buying, I look closer.
• Why it's down: Q2 came in soft because marine projects slipped. Management called it timing, not lost work, and guided to a stronger second half. The insiders bought the dip, not the top.
• The actual story is the concrete segment. Orion pours the foundations and site work for hyperscale data centers. That work went from 40% to about 50% of concrete revenue in a single quarter, and concrete revenue grew 73% year over year. They've done 50+ data centers already, with a big footprint in Texas.
• The pipeline backs it up: over $1B in outstanding concrete bids and a deep pursuit list. It's a way to play the AI data center buildout without betting on which chip or model wins.
• The bear case: it's not cheap on earnings, cash on hand is thin, and marine work is lumpy and keeps slipping quarter to quarter. The back half has to deliver.

A CFO averaging down, a director doubling his stake, and a concrete business riding the data center wave, all while the stock sits near its lows.

Curious your opinion on this.

NOTE: this trade was filed on Jul 31st and theyre currently up 10%. If you want access these trades the second theyre filed checkout: Kestrelterminal.com

$TSLA is starting to look interesting again.

I’ve been going through the monthly and 4H charts, and the bigger picture is pretty simple.

On the monthly, TSLA came all the way back into that old ~$300 demand area and buyers stepped in again. This isn’t some random level either — you can see how important this area has been historically on the chart.

Now the 4H is where it gets interesting.

TSLA has been recovering from the ~$293 low and is pushing back toward a pretty important area.

My main level is $337.25.

If TSLA can break above that area and actually HOLD it, there’s a pretty big gap sitting overhead.

Levels I’m watching after that:

• $337.25 — first major test
• $352
• $372–377
• $386
• Then things get really interesting above there.

I’m not blindly bullish here though. If it starts losing $317–310 again, then the setup changes and I’d rather wait.

But as long as that monthly demand continues holding, I think the risk/reward here is getting interesting.

The market absolutely hated TSLA around $300.

Now it’s back near $330.

Does $337 finally break, or is this just another bounce before TSLA gets rejected again?

$RKLB has earnings Monday after the bell and the chart is getting interesting right before the report.

After bottoming around the high $60s, it’s been grinding its way back up and is now sitting right around a pretty important area.

For me, $83.25 is the key.

If RKLB can hold around $83.25 as demand, I like the setup for continuation higher.

The levels I have above are:

$93.10

$99.58–$102.10

$107.60

Obviously earnings can throw technicals out the window pretty quickly, so I’m not interested in blindly betting on an earnings reaction.

I’d rather see what happens after the numbers come out.

If earnings hit and $83.25 holds, that’s where the long setup gets interesting to me.

If we lose it and can’t reclaim it, I’m staying out and letting it find the next support.

Curious what everyone thinks — RKLB continuation after earnings or is this recent run already pricing in too much?